NASDAQ:ICLR Icon Q1 2026 Earnings Report $116.78 +0.21 (+0.18%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$115.47 -1.31 (-1.12%) As of 05/22/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Icon EPS ResultsActual EPSN/AConsensus EPS $2.95Beat/MissN/AOne Year Ago EPSN/AIcon Revenue ResultsActual RevenueN/AExpected Revenue$1.99 billionBeat/MissN/AYoY Revenue GrowthN/AIcon Announcement DetailsQuarterQ1 2026Date5/27/2026TimeAfter Market ClosesConference Call DateWednesday, May 27, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Icon Earnings HeadlinesIcon (NASDAQ:ICLR) Given New $120.00 Price Target at JPMorgan Chase & Co.May 19, 2026 | americanbankingnews.comIcon (NASDAQ:ICLR) Coverage Initiated by Analysts at Royal Bank Of CanadaMay 19, 2026 | americanbankingnews.comThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000. | Behind the Markets (Ad)Icon Plc (NASDAQ:ICLR) Receives Consensus Recommendation of "Hold" from BrokeragesMay 17, 2026 | americanbankingnews.comIs It Time To Revisit ICON (ICLR) After Its Recent Share Price Rebound?May 13, 2026 | finance.yahoo.comICON expands US early phase research capabilities with new clinic and outpatient centresMay 13, 2026 | businesswire.comSee More Icon Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Icon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Icon and other key companies, straight to your email. Email Address About IconIcon (NASDAQ:ICLR) (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas. Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions. The company leverages proprietary technology platforms and advanced data analytics to optimize trial efficiency, support patient recruitment and enhance site management, with the goal of accelerating development timelines and mitigating risks. Founded in 1990 by John F. Climax, Icon is headquartered in Dublin, Ireland, and has expanded through organic growth and strategic acquisitions to serve clients around the world. The company maintains regional offices and operational centers across North America, Europe, Asia-Pacific, Latin America and the Middle East, providing localized regulatory support and scientific expertise to a diverse client base. Icon’s leadership team is headed by Chief Executive Officer Steve Cutler, who joined the company in 2017 and brings extensive experience in clinical research and development. Under his stewardship, Icon continues to invest in digital innovation, strategic partnerships and talent development to meet the evolving needs of drug and device developers globally.View Icon ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
